Skip to content

Alumis Inc. ALMS Finance Lease Liabilities

Finance Lease Liabilities at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$48K-69.2%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$48.18M-15.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.15M-39.7%
Incyte logo
IncyteINCY
$29.41M-9.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$0-100%
Insmed logo
InsmedINSM
$19.82M-14.8%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.

The official record: Alumis Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s finance lease liabilities?
Alumis Inc. (ALMS) reported finance lease liabilities of $0 in Q4 2025.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.